News Daily News FDA Approves Lerodalcibep for Adults With Hypercholesterolemia Yael L. Maxwell December 15, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN Michael O'Riordan July 29, 2024
News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Daily News Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets Michael O'Riordan September 14, 2023
News Daily News USPSTF: Screening Kids for Lipid Disorders Still Needs More Data Shelley Wood July 18, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Daily News How Lp(a) Levels Compare With LDL-C in FH: Some Surprises Michael O'Riordan November 17, 2022
News Daily News Statin Use, at Any Dose, Not Linked to Excess Dementia Risk in FH Yael L. Maxwell April 22, 2022
News Daily News Homozygous FH Diagnosis Often Comes Late, With Lackluster Care Michael O'Riordan February 10, 2022
News Daily News Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study Yael L. Maxwell January 03, 2022
News Daily News FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels Michael O'Riordan December 22, 2021
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News Cumulative Burden of LDL Cholesterol Increases CHD Risk Michael O'Riordan September 23, 2021
News Daily News Heterozygous FH Diagnosed Late, Remains Undertreated Michael O'Riordan September 13, 2021
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021